Abstract:Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which are simple to engineer and can reliably achieve high levels of protein expression. However, plasmids typically require antibiotics for maintenance, and the administration of an antibiotic is often incompatible with in vivo experimentation or treatment. EcN natively contains plasmids pMUT1 and pMUT2, which have no known function but are stable within the bacteria. Here, we describe the development of the pMUT plasmids into a robust platform for engineering EcN for in vivo experimentation, alongside a CRISPR-Cas9 system to remove the native plasmids. We systematically engineered both pMUT plasmids to contain selection markers, fluorescent markers, temperature sensitive expression, and curli secretion systems to export a customizable functional material into the extracellular space. We then demonstrate that the engineered plasmids were maintained in bacteria as the engineered bacteria pass through the mouse GI tract without selection, and that the secretion system remains functional, exporting functionalized curli proteins into the gut. Our plasmid system presents a platform for the rapid development of therapeutic EcN bacteria.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00466?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00466</a>.Table S1: DNA primers used in this work; Table S2: Sequence of UNS sequences; Table S3: gRNA sequences used in the pFREE and pCryptDel plasmids; Table S4: Variant TlpA* promoter sequences, and their properties; Figure S1: Detailed plasmid maps of pMUT1 and pMUT2; Figure S2: GFP and RFP characterization of engineered pMUT plasmids; Figure S3: Plasmid vectors to cure EcN cryptic plasmids; Figure S4: Curing native pMUT plasmids; Figure S5: In vivo synthetic plasmid loss; Supplementary methods for Figure S5; Figure S6: In vitro growth characterization of bacteria used in vivo (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_001.pdf">PDF</a>)Dataset S1: All data used in the figures (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_002.xlsx">XLSX</a>)Dataset S2: In vivo data (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications

Expanding the toolbox of probiotic Escherichia coli Nissle 1917 for synthetic biology

Expanding the Toolbox of Probioticescherichia Colinissle 1917 for Synthetic Biology

Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies

Expectations for employing Escherichia coli Nissle 1917 in food science and nutrition

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy

Comprehensive Analysis of the Physiological Characterization of Escherichia coli Nissle 1917

Development of probiotic E. coli Nissle 1917 for β-alanine production by using protein and metabolic engineering

Systems Metabolic Engineering to Elucidate and Enhance Intestinal Metabolic Activities of Escherichia coli Nissle 1917

Engineering E. coli strains using antibiotic-resistance-gene-free plasmids

Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties

Improved cryptic plasmids in probiotic Escherichia coli Nissle 1917 for antibiotic-free pathway engineering

Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917

Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability

Development of Escherichia coli Nissle 1917 derivative by CRISPR/Cas9 and application for gamma-aminobutyric acid (GABA) production in antibiotic-free system

Recent progress in therapeutic natural product biosynthesis using Escherichia coli

Engineering of Therapeutic Proteins Production in Escherichia coli

Efficient markerless integration of genes in the chromosome of probiotic E. coli Nissle 1917 by bacterial conjugation

Bioengineering of Escherichia coli Nissle 1917 for Production and Excretion of Spermidine, a Key Metabolite in Human Health

Omics-guided bacterial engineering of Escherichia coli ER2566 for recombinant protein expression

Minimizing endogenous cryptic plasmids to construct antibiotic-free expression systems for Escherichia coli Nissle 1917